Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents)
  4. Volume 22, Issue 4
  5. Article
Volume 22, Issue 4
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

Introduction

Natural medicine (NM) has been used since ancient times for therapeutic purposes worldwide. Presently, the combination of clopidogrel and NM with a reasonable synergistic effect has gained increasing acceptance in clinical therapeutics.

Methods

Here, we have performed a comprehensive retrieval of literature published in both English and Chinese databases until August 1, 2022, studying the synergistic interactions of clopidogrel and NM through pharmacokinetic/pharmacodynamic (PK-PD) analyses. We retrieved 7, 3, and 5 studies on PK analysis and 3, 3, and 8 studies on PD analysis for the interaction of clopidogrel with single herbal medicines, bioactive compounds, and herbal prescriptions, respectively. Most studies on NM have been found to mainly focus on preclinical observations, and there have been fewer clinical PK analyses.

Results

A potential drug-herb interaction has been observed to occur when clopidogrel and NM were metabolized by an enzyme network comprising P-gp, CES1, and CYP450. In contrast, most PD studies have focused on clinical observations, and few preclinical findings have been reported. Some cases have suggested that the combination of the two types of drugs would alter the antiplatelet efficacy and adverse effects. Studies on PK, however, have shown significant or slightly varying results for the drug prototype and its metabolites.

Conclusion

In the combination therapies, the interaction between clopidogrel and NM was found to alter antiplatelet aggregation pathways and P2Y12 receptor function.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chamc/10.2174/1871525722666230907112509
2024-12-01
2024-11-22

  • From This Site

    /content/journals/chamc/10.2174/1871525722666230907112509
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FeiginV.L. StarkB.A. JohnsonC.O. RothG.A. BisignanoC. AbadyG.G. AbbasifardM. Abbasi-KangevariM. Abd-AllahF. AbediV. AbualhasanA. Abu-RmeilehN.M.E. AbushoukA.I. AdebayoO.M. AgarwalG. AgasthiP. AhinkorahB.O. AhmadS. AhmadiS. Ahmed SalihY. AjiB. AkbarpourS. AkinyemiR.O. Al HamadH. AlahdabF. AlifS.M. AlipourV. AljunidS.M. AlmustanyirS. Al-RaddadiR.M. Al-Shahi SalmanR. Alvis-GuzmanN. AncuceanuR. AnderliniD. AndersonJ.A. AnsarA. AntonazzoI.C. ArablooJ. ÄrnlövJ. ArtantiK.D. AryanZ. AsgariS. AshrafT. AtharM. AtreyaA. AusloosM. BaigA.A. BaltatuO.C. BanachM. BarbozaM.A. Barker-ColloS.L. BärnighausenT.W. BaroneM.T.U. BasuS. BazmandeganG. BeghiE. BeheshtiM. BéjotY. BellA.W. BennettD.A. BensenorI.M. BezabheW.M. BezabihY.M. BhagavathulaA.S. BhardwajP. BhattacharyyaK. BijaniA. BikbovB. BirhanuM.M. BoloorA. BonnyA. BrauerM. BrennerH. BryazkaD. ButtZ.A. Caetano dos SantosF.L. Campos-NonatoI.R. Cantu-BritoC. CarreroJ.J. Castañeda-OrjuelaC.A. CatapanoA.L. ChakrabortyP.A. CharanJ. ChoudhariS.G. ChowdhuryE.K. ChuD-T. ChungS-C. ColozzaD. CostaV.M. CostanzoS. CriquiM.H. DadrasO. DagnewB. DaiX. DalalK. DamascenoA.A.M. D’AmicoE. DandonaL. DandonaR. Darega GelaJ. DavletovK. De la Cruz-GóngoraV. DesaiR. DhamnetiyaD. DharmaratneS.D. DhimalM.L. DhimalM. DiazD. DichgansM. DokovaK. DoshiR. DouiriA. DuncanB.B. EftekharzadehS. EkholuenetaleM. El NahasN. ElgendyI.Y. ElhadiM. El-JaafaryS.I. EndresM. EndriesA.Y. ErkuD.A. FaraonE.J.A. FarooqueU. FarzadfarF. FerozeA.H. FilipI. FischerF. FloodD. GadM.M. GaidhaneS. Ghanei GheshlaghR. GhashghaeeA. GhithN. GhozaliG. GhozyS. GialluisiA. GiampaoliS. GilaniS.A. GillP.S. GnedovskayaE.V. GolechhaM. GoulartA.C. GuoY. GuptaR. GuptaV.B. GuptaV.K. GyanwaliP. Hafezi-NejadN. HamidiS. HanifA. HankeyG.J. HargonoA. HashiA. HassanT.S. HassenH.Y. HavmoellerR.J. HayS.I. HayatK. HegazyM.I. HerteliuC. HollaR. HostiucS. HousehM. HuangJ. HumayunA. HwangB-F. IacovielloL. IavicoliI. IbitoyeS.E. IlesanmiO.S. IlicI.M. IlicM.D. IqbalU. IrvaniS.S.N. IslamS.M.S. IsmailN.E. IsoH. IsolaG. IwagamiM. JacobL. JainV. JangS-I. JayapalS.K. JayaramS. JayawardenaR. JeemonP. JhaR.P. JohnsonW.D. JonasJ.B. JosephN. JozwiakJ.J. JürissonM. KalaniR. KalhorR. KalkondeY. KamathA. KamiabZ. KanchanT. KandelH. KarchA. KatotoP.D.M.C. KayodeG.A. KeshavarzP. KhaderY.S. KhanE.A. KhanI.A. KhanM. KhanM.A.B. KhatibM.N. KhubchandaniJ. KimG.R. KimM.S. KimY.J. KisaA. KisaS. KivimäkiM. KolteD. KoolivandA. Koulmane LaxminarayanaS.L. KoyanagiA. KrishanK. KrishnamoorthyV. KrishnamurthiR.V. KumarG.A. KusumaD. La VecchiaC. LaceyB. LakH.M. LallukkaT. LasradoS. LavadosP.M. LeonardiM. LiB. LiS. LinH. LinR-T. LiuX. LoW.D. LorkowskiS. LucchettiG. Lutzky SauteR. Magdy Abd El RazekH. MagnaniF.G. MahajanP.B. MajeedA. MakkiA. MalekzadehR. MalikA.A. ManafiN. MansourniaM.A. MantovaniL.G. MartiniS. MazzagliaG. MehndirattaM.M. MenezesR.G. MeretojaA. MershaA.G. Miao JonassonJ. MiazgowskiB. MiazgowskiT. MichalekI.M. MirrakhimovE.M. MohammadY. Mohammadian-HafshejaniA. MohammedS. MokdadA.H. MokhayeriY. MolokhiaM. MoniM.A. MontasirA.A. MoradzadehR. MorawskaL. MorzeJ. MuruetW. MusaK.I. NagarajanA.J. NaghaviM. Narasimha SwamyS. NascimentoB.R. NegoiR.I. Neupane KandelS. NguyenT.H. NorrvingB. NoubiapJ.J. NwatahV.E. OanceaB. OdukoyaO.O. OlagunjuA.T. OrruH. OwolabiM.O. PadubidriJ.R. PanaA. ParekhT. ParkE-C. Pashazadeh KanF. PathakM. PeresM.F.P. PerianayagamA. PhamT-M. PiradovM.A. PodderV. PolinderS. PostmaM.J. PourshamsA. RadfarA. RafieiA. RaggiA. RahimF. Rahimi-MovagharV. RahmanM. RahmanM.A. RahmaniA.M. RajaiN. RanasingheP. RaoC.R. RaoS.J. RathiP. RawafD.L. RawafS. ReitsmaM.B. RenjithV. RenzahoA.M.N. RezapourA. RodriguezJ.A.B. RoeverL. RomoliM. RynkiewiczA. SaccoS. SadeghiM. Saeedi MoghaddamS. SahebkarA. Saif-Ur-RahmanK.M. SalahR. SamaeiM. SamyA.M. SantosI.S. Santric-MilicevicM.M. SarrafzadeganN. SathianB. SattinD. SchiavolinS. SchlaichM.P. SchmidtM.I. SchutteA.E. SepanlouS.G. SeylaniA. ShaF. ShahabiS. ShaikhM.A. ShannawazM. ShawonM.S.R. SheikhA. SheikhbahaeiS. ShibuyaK. SiabaniS. SilvaD.A.S. SinghJ.A. SinghJ.K. SkryabinV.Y. SkryabinaA.A. SobaihB.H. StorteckyS. StrangesS. TadesseE.G. TariganI.U. TemsahM-H. TeuschlY. ThriftA.G. TonelliM. Tovani-PaloneM.R. TranB.X. TripathiM. TsegayeG.W. UllahA. UnimB. UnnikrishnanB. VakilianA. Valadan TahbazS. VasankariT.J. VenketasubramanianN. VervoortD. VoB. VoloviciV. VosoughiK. VuG.T. VuL.G. WafaH.A. WaheedY. WangY. WijeratneT. WinklerA.S. WolfeC.D.A. WoodwardM. WuJ.H. Wulf HansonS. XuX. YadavL. YadollahpourA. Yahyazadeh JabbariS.H. YamagishiK. YatsuyaH. YonemotoN. YuC. YunusaI. ZamanM.S. ZamanS.B. ZamanianM. ZandR. ZandifarA. ZastrozhinM.S. ZastrozhinaA. ZhangY. ZhangZ-J. ZhongC. ZunigaY.M.H. MurrayC.J.L. Global, regional, and national burden of stroke and its risk factors, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019.Lancet Neurol.2021201079582010.1016/S1474‑4422(21)00252‑0 34487721
     [Google Scholar]
  2. ScheitzJ.F. SposatoL.A. Schulz-MengerJ. NolteC.H. BacksJ. EndresM. Stroke-heart syndrome: Recent Advances and Challenges.J. Am. Heart Assoc.20221117e02652810.1161/JAHA.122.026528 36056731
     [Google Scholar]
  3. MatsumaruY. KitazonoT. KadotaK. NakaoK. NakagawaY. ShiteJ. YokoiH. KozumaK. TanabeK. AkasakaT. ShinkeT. UenoT. HirayamaA. UemuraS. KurodaT. TakitaA. HaradaA. IijimaR. MurakamiY. SaitoS. NakamuraM. Relationship between platelet aggregation and stroke risk after percutaneous coronary intervention: A PENDULUM analysis.Heart Vessels202237694295310.1007/s00380‑021‑02003‑w 34973085
     [Google Scholar]
  4. KhalilP. KabbachG. Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: A review.Curr. Cardiol. Rep.2019211510.1007/s11886‑019‑1088‑x 30689068
     [Google Scholar]
  5. MotovskaZ. KalaP. Benefits and risks of clopidogrel use in patients with coronary artery disease: Evidence from randomized studies and registries.Clin. Ther.200830Pt 22191220210.1016/j.clinthera.2008.12.001 19281914
     [Google Scholar]
  6. TanB.E.X. WongP.Y. BaibhavB. ThakkarS. AzharA.Z. RaoM. CheungJ.W. Clopidogrel vs aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysis.Curr. Probl. Cardiol.202348810117410.1016/j.cpcardiol.2022.101174 35341798
     [Google Scholar]
  7. GuoM. WangT. YangJ. ChangH. JiS. TangD. Interaction of clopidogrel and fufang danshen dripping pills assay in coronary heart disease based on non-target metabolomics.J. Ethnopharmacol.201923418919610.1016/j.jep.2019.01.030 30703494
     [Google Scholar]
  8. ShaikB.B. KatariN.K. JonnalagaddaS.B. Role of natural products in developing novel anticancer agents: A Perspective.Chem. Biodivers.20221911e20220053510.1002/cbdv.202200535 36347633
     [Google Scholar]
  9. PotenzaM.A. MontagnaniM. SantacroceL. CharitosI.A. BottalicoL. Ancient herbal therapy: A brief history of Panax ginseng.J. Ginseng Res.202347335936510.1016/j.jgr.2022.03.004 37252279
     [Google Scholar]
  10. BhandariM. RajS. ManchandaR. AlamM.S. Review on natural bioactive products as radioprotective therapeutics: Present and Past Perspective.Curr. Pharm. Biotechnol.202223141721173810.2174/1389201023666220110104645 35016594
     [Google Scholar]
  11. ChenX. JinJ. ChenY. PengL. ZhongG. LiJ. BiH. CaiY. HuangM. Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats.Biopharm. Drug Dispos.2015361646810.1002/bdd.1918 25256597
     [Google Scholar]
  12. BarriusoI. WornerF. VilahurG. Novel antithrombotic agents in ischemic cardiovascular disease: Progress in the search for the optimal treatment.J. Cardiovasc. Dev. Dis.202291139710.3390/jcdd9110397 36421932
     [Google Scholar]
  13. ZhangZ. WangY. TanW. WangS. LiuJ. LiuX. WangX. GaoX. A review of danshen combined with clopidogrel in the treatment of coronary heart disease.Evid. Based Complement. Alternat. Med.2019201911710.1155/2019/2721413 30911318
     [Google Scholar]
  14. YinQ. ZhangX. LiaoS. HuangX. WanC.C. WangY. Potential anticoagulant of traditional chinese medicine and novel targets for anticoagulant drugs.Phytomedicine202311615488010.1016/j.phymed.2023.154880 37267694
     [Google Scholar]
  15. MaS. DaiG. BiX. GongM. MiaoC. ChenH. GaoL. ZhaoW. LiuT. ZhangN. The herb-drug interaction of clopidogrel and xuesaitong dispersible tablet by modulation of the pharmacodynamics and liver carboxylesterase 1A metabolism.Evid. Based Complement. Alternat. Med.201820181810.1155/2018/5651989 30498515
     [Google Scholar]
  16. MaS. JuW. DaiG. ZhaoW. ChengX. FangZ. TanH. WangX. Synergistic effects of clopidogrel and fufang danshen dripping pills by modulation of the metabolism target and pharmacokinetics.Evid. Based Complement. Alternat. Med.201420141810.1155/2014/789142 25530790
     [Google Scholar]
  17. MaS.T. DaiG.L. BiX.L. GongM.R. XiongY.Y. JuW.Z. TanH.S. [Synergistic effects of clopidogrel and xuesaitong dispersible tablet by modulating plasma protein Binding].Zhong Yao Cai2016394872875 30132623
     [Google Scholar]
  18. MaS.T. DaiG.L. ChengX.G. ZhaoW.Z. SunB.T. JuW.Z. TanH.S. [Synergistic action of compound danshen dripping pill (CDDP) on clopidogrel bisulfate (CPG) counteracting platelet aggregation].Zhong Yao Cai2014371018201825 25895391
     [Google Scholar]
  19. MaS. ZhangN. HongG. FengC.T. HongS.W. DaiG.L. Unraveling the action mechanism of buyang huanwu tang (BYHWT) for cerebral ischemia by systematic pharmacological methodology.Comb. Chem. High Throughput Screen.20212471114112510.2174/1386207323666200901100529 32875974
     [Google Scholar]
  20. MaS-T. DalG.L. ChengX.G. ZhaoW.Z. SunB.T. JuW.Z. TanH.S. [Effect of clopidogrel on plasma protein binding rates of ginsenoside Rg1].Zhongguo Zhong Xi Yi Jie He Za Zhi.2017374480484
     [Google Scholar]
  21. SiaC.H. TanS.H. ChanS.P. MarchesseauS. SimH.W. CarvalhoL. ChenR. AminN.H.M. FongA.Y.Y. RichardsA.M. YipC. ChanM.Y. Enhanced thrombin generation is associated with worse left ventricular scarring after ST-segment elevation myocardial infarction: A Cohort Study.Pharmaceuticals (Basel)202215671810.3390/ph15060718 35745638
     [Google Scholar]
  22. ZakariaZ. FongA. BadhanR. Clopidogrel pharmacokinetics in malaysian population groups: The impact of inter-ethnic variability.Pharmaceuticals (Basel)20181137410.3390/ph11030074 30049953
     [Google Scholar]
  23. QianY. MarkowitzJ.S. Natural products as modulators of CES1 activity.Drug Metab. Dispos.20204810993100710.1124/dmd.120.000065 32591414
     [Google Scholar]
  24. ZhouC. XuM. YuH. ZhengX.T. ZhongZ.F. ZhangL. Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.Food Chem. Toxicol.201811930230810.1016/j.fct.2018.02.051 29496531
     [Google Scholar]
  25. LeeJ.H. ShinY.J. KimH.J. OhJ.H. JangY.P. LeeY.J. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb–drug interactions.Int. J. Pharm.20114101-2687410.1016/j.ijpharm.2011.03.031 21421030
     [Google Scholar]
  26. DengY. MoY. ChenX. ZhangL. LiaoC. SongY. XuC. Effect of Ginkgo Biloba extract on the pharmacokinetics and metabolism of clopidogrel in rats.Phytother. Res.201630111886189210.1002/ptr.5691 27487816
     [Google Scholar]
  27. ChenX. ZhaoZ. ChenY. GouX. ZhouZ. ZhongG. CaiY. HuangM. JinJ. Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats.J. Ethnopharmacol.201619236236910.1016/j.jep.2016.07.066 27459888
     [Google Scholar]
  28. XiaoM. QianC. LuoX. YangM. ZhangY. WuC. MokC. LeeP. ZuoZ. Impact of the Chinese herbal medicines on dual antiplatelet therapy with clopidogrel and aspirin: Pharmacokinetics and pharmacodynamics outcomes and related mechanisms in rats.J. Ethnopharmacol.201923510011010.1016/j.jep.2019.01.040 30710735
     [Google Scholar]
  29. GongE. CheaS. BalupuriA. KangN. ChinY.W. ChoiY. Enzyme kinetics and molecular docking studies on cytochrome 2B6, 2C19, 2E1, and 3A4 activities by sauchinone.Molecules201823355510.3390/molecules23030555 29498658
     [Google Scholar]
  30. LiuA.C. ZhaoL.X. LouH.X. Curcumin alters the pharmacokinetics of warfarin and clopidogrel in Wistar rats but has no effect on anticoagulation or antiplatelet aggregation.Planta Med.2013791197197710.1055/s‑0032‑1328652 23807811
     [Google Scholar]
  31. LiY. LiuC. ZhangY. MiS. WangN. Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats.J. Ethnopharmacol.2011137156256710.1016/j.jep.2011.06.011 21704146
     [Google Scholar]
  32. AlkharfyK. JanB. AlotaibiK. AlotaibiA. AlqahtaniS. RaishM. AhmadA. Clopidogrel-herb interactions: A pharmacokinetic and pharmacodynamic assessment in a rat model.Curr. Drug Metab.2021221296997710.2174/1389200222666211029152151 34719359
     [Google Scholar]
  33. TianX. Effects of Rong Shuan capsule, Xue Zhi Kang capsule, Xin Yuan capsule and Songling Xue Mai Kang capsule on the pharmacokinetics of clopidogrel active metabolite in rats.J. Chin. Pharm. Sci.2017263187195
     [Google Scholar]
  34. JiS. ShaoX. SuZ. JiL. WangY. MaY. ZhaoL. DuY. GuoM. TangD. Segmented scan modes and polarity-based LC-MS for pharmacokinetic interaction study between Fufang Danshen Dripping Pill and Clopidogrel Bisulfate Tablet.J. Pharm. Biomed. Anal.201917436737510.1016/j.jpba.2019.05.055 31202879
     [Google Scholar]
  35. MengK. ZhuH. SongX. Effects of panax notoginseng combinating with dual antiplatelet drugs on the major adverse cardiovascular events in pafients undergoing percutaneous coronary intervention procedure.Chin. Med.20138445447
     [Google Scholar]
  36. ZhaoJ. GengW.J. ZhaiB.Z. Clinical observation on Xueshuantong Injection in treatment of acute cerebral infarction patients with Clopidogrel resistance.2015Available From:10.7501/j.issn.0253‑2670.2015.14.018
     [Google Scholar]
  37. LauW.C. WelchT.D. ShieldsT. RubenfireM. TantryU.S. GurbelP.A. The effect of St John’s Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: Increased platelet inhibition by enhancement of CYP3A4 metabolic activity.J. Cardiovasc. Pharmacol.2011571869310.1097/FJC.0b013e3181ffe8d0 20980920
     [Google Scholar]
  38. TranaC. TothG. WijnsW. BarbatoE.St. John’s Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: A single-center randomized open-label trial (St. John’s Trial).J. Cardiovasc. Transl. Res.20136341141410.1007/s12265‑013‑9455‑2 23463297
     [Google Scholar]
  39. ChungJ.W. KimS.J. HwangJ. LeeM.J. LeeJ. LeeK.Y. ParkM.S. SungS.M. KimK.H. JeonP. BangO.Y. Comparison of clopidogrel and ticlopidine/Ginkgo biloba in patients with clopidogrel resistance and carotid stenting.Front. Neurol.2019104410.3389/fneur.2019.00044 30761076
     [Google Scholar]
  40. LiY. WangN. Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel.J. Ethnopharmacol.2010128362362810.1016/j.jep.2010.02.003 20176099
     [Google Scholar]
  41. GaoB. HuangL. LiuH. WuH. ZhangE. YangL. WuX. WangZ. Platelet P2Y 12 receptors are involved in the haemostatic effect of notoginsenoside Ft1, a saponin isolated from Panax notoginseng.Br. J. Pharmacol.2014171121422310.1111/bph.12435 24117220
     [Google Scholar]
  42. LiuY. LiuT. ZhaoJ. HeT. ChenH. WangJ. ZhangW. MaW. FanY. SongX. Phospholipase Cγ2 signalling contributes to the haemostatic effect of Notoginsenoside Ft1.J. Pharm. Pharmacol.201971587888610.1111/jphp.13057 30549041
     [Google Scholar]
  43. HuS. BelcaroG. DugallM. PeterzanP. HosoiM. LeddaA. RivaA. GiacomelliL. TogniS. EggenhoffnerR. CotelleseR. Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva®).Eur. Rev. Med. Pharmacol. Sci.2018221550425046 30070343
     [Google Scholar]
  44. DucciK. LiistroF. PortoI. VentoruzzoG. AngioliP. FalsiniG. VergalloR. BologneseL. Ticagrelor versus clopidogrel in patients undergoing implantation of paclitaxel-eluting stent in the femoropopliteal district: A randomized pilot study using frequency-domain optical coherence tomography.Int. J. Cardiol.202030419219710.1016/j.ijcard.2020.01.024 32007230
     [Google Scholar]
  45. MatsuoM. ItoH. TakemuraY. HattoriM. KawakamiM. TakahashiN. YamazakiM. Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: A retrospective pilot study.J. Anesth.201731463163510.1007/s00540‑017‑2362‑y 28451807
     [Google Scholar]
  46. ZhangL. LiuN. ZhangJ. ZhangH. Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome.Pak. J. Pharm. Sci.2016296Suppl.23032306 28167470
     [Google Scholar]
  47. LiJ. JuJ. ChenZ. LiuJ. LuF. GaoR. XuH. Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: Study protocol for a cluster randomized controlled trial.Trials20181919310.1186/s13063‑017‑2373‑x 29415754
     [Google Scholar]
/content/journals/chamc/10.2174/1871525722666230907112509
Loading
Drug-herb Synergistic Interactions between Clopidogrel and Natural Medicine
Cardiovasc. Hematol. Agents Med. Chem. 22, 421 (2024); https://doi.org/10.2174/1871525722666230907112509
/content/journals/chamc/10.2174/1871525722666230907112509
/content/journals/chamc/10.2174/1871525722666230907112509
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Review Article
Keyword(s): clinical therapeutics; clopidogrel; Natural medicine; pharmacodynamic; pharmacokinetic; synergistic effect

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test